On July 21, Iluvatar CoreX rose 5.77% in regular trading, trading at HK$528.0/share, with turnover of HK$71.85 million.
On the news front, Goldman Sachs recently initiated coverage on Iluvatar CoreX with a Buy rating and a 12-month target price of HK$1,000, implying approximately 85% upside from current levels. Goldman Sachs' core thesis centers on rising AI capital expenditure in China directly driving domestic chip demand, with Iluvatar CoreX positioned as a leading beneficiary. The bank forecasts net profit turning positive by 2027 and operating expense ratio declining from 156% in 2025 to 23% by 2030.
Simultaneously, the company officially launched its next-generation flagship GPU, Tiangai 300, at the World Artificial Intelligence Conference. The product is supported by a comprehensive ecosystem spanning hardware, software, and systems. Goldman Sachs joins Macquarie (target HK$1,240), Bank of America (target HK$1,013), and JPMorgan (target HK$920) in bullish coverage of the stock.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments